← ANALYST RATINGS · TIPRANKS

Generate Biomedicines, Inc. (GENB): analyst forecast and price target

$12.09 −7.43% close 16.10.26 · market cap $1.6B · General · Biotechnology IWM 0.01%
Price targets and ratings of

Analyst consensus

Strong Buy

3 Buy0 Hold0 Sell

Ratings of 3 analysts in the last 3 months

12-month forecast

$26.00+115.1% upside

Based on 3 price targets given in the last 3 months, the average target is $26.00, the highest $30.00, the lowest $22.00. The average is +115.1% from the last price of $12.09.

$20.00$30.00AprJulOctJan 27AprJulOctHigh$30.00Average$26.00Low$22.00
Highest target $30.00 Average target $26.00 Lowest target $22.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright $30.00 Buy +148.1% Reiterated 14.10.26on TipRanks 10:35 +3.2%next day +4.0%
Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% Piper Sandler $26.00 Buy +115.1% Reiterated 14.10.26on TipRanks 07:25 +3.2%next day +4.0%
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright $30.00 Buy +148.1% Reiterated 05.10.26on TipRanks 06:45 +0.9%next day −1.3% · 5 days −0.9%
Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% Piper Sandler $26.00 Buy +115.1% Reiterated 02.10.26on TipRanks 07:15 −1.5%next day +0.9% · 5 days +3.6%
Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% H.C. Wainwright $30.00 Buy +148.1% Reiterated 09.09.26on TipRanks Sep 8 11:55 −2.4%next day −1.9% · 5 days +2.9%
Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% Morgan Stanley $22.00 Buy +82.0% Assigned 17.08.26on TipRanks 08:55 +0.8%next day +3.2% · 5 days +14.1%
Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% Piper Sandler $24.00 Buy +98.5% Reiterated 07.08.26on TipRanks 08:01 +2.7%next day +2.6% · 5 days +8.6%
Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% Guggenheim $30.00 Buy +148.1% Reiterated 24.06.26on TipRanks Jun 25 07:50 +5.2%next day +1.0% · 5 days 0.0%
Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% Goldman Sachs $26.00 Buy +115.1% Reiterated 09.04.26on TipRanks Apr 10 13:40 −4.0%next day −1.0% · 5 days +6.2%
Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% Cantor Fitzgerald — Buy — Initiated 24.03.26on TipRanks 06:30 −3.6%next day −2.2% · 5 days +4.3%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Generate Biomedicines, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Sean Laaman★★★★★★★★★★Morgan Stanley · #446
Hits 67%185 of 275 Average return +17.2%
1 year Sean Laaman★★★★★★★★★★Morgan Stanley · #446
Hits 67%185 of 275 Average return +17.2%
2 years Sean Laaman★★★★★★★★★★Morgan Stanley · #446
Hits 67%185 of 275 Average return +17.2%

Most profitable

3 months Edward Tenthoff★★★★★★★★★★Piper Sandler · #3650
Hits 41%199 of 487 Average return +3.5%
1 year Edward Tenthoff★★★★★★★★★★Piper Sandler · #3650
Hits 41%199 of 487 Average return +3.5%
2 years Edward Tenthoff★★★★★★★★★★Piper Sandler · #3650
Hits 41%199 of 487 Average return +3.5%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.33 at a price of $15.02 (+68.7%); now: $26.00 at $12.09 (+115.1%).

$15.00$20.00$25.00Sep 15Oct 1Oct 15Top analysts$26.00Average target$26.00Price$12.09

PriceAverage targetTop analysts’ target

Recommendation trend

025710Oct 25NovDecJan 26Feb32Mar43Apr64May52Jun41Jul51Aug41Sep81Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy654548
Buy421111
Hold000000
Sell000000

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Data from the stock’s TipRanks forecast page, read 120 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗